who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Winston Wright of Alto, Serafina Lalany of Houston Exponential, and Zeev Braude of SiteAware. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from startup development to construction technology — recently making headlines in Houston innovation.

Winston Wright, Houston general manager at Alto

Winston Wright leads Houston operations for Dallas-based Alto, which is taking on the likes of Uber and Lyft. Photo courtesy of Alto

As any Houstonian knows, the city is quite large. While Dallas-based Alto, a luxury rideshare service, rolled out in Houston a while ago, Winston Wright has plans to make sure the company is covering the entire greater Houston area.

Wright, who's the Houston general manager for Alto, joined last week's episode of the Houston Innovators Podcast. He shares more on Alto's future in Texas and beyond, as well as what's challenging him most as he grows the team locally.

"The vision I have for this market is that, as we move forward and continue to expand, that we're covering all of Houston," he says. Click here to read more and to listen to the episode.

Serafina Lalany, executive director of Houston Exponential

Houston Exponential appoints new executive director and restructures its boardHX has its new permanent leader. Photo courtesy of Serafina Lalany

It's a new era for Houston Exponential, and Serafina Lalany, named the organization's executive director last September, is leading HX into its new phase.

"The interesting thing of being an organization of ex-startup operators is that we operate as a startup ourselves," she tells InnovationMap. "Along the journey of supporting and building infrastructure for a startup community, we have also been seeking our own product market fit. I think we're at the place now where we have a profound realization of what that is and who we serve. We have crystal clear vision around that."

Lalany discusses more of her plans for HX for 2022 and shares how the organization is evolving to be what Houston's innovation ecosystem needs in an interview. Click here to read more.

Zeev Braude, CEO of SiteAware

Houston-based SiteAware has raised $15 million in its latest round of funding. Photo courtesy of SiteAware

SiteAware, a Houston construction software startup, raised $15 million in its series B round, which was led by Singapore-based Vertex Ventures Israel. Existing investors Robert Bosch Venture Capital GmbH, Axon Ventures, Oryzn Capital, The Flying Object, and lool Ventures also contributed to the round.

The company's digital construction verification, or DCV, platform uses AI and digital twin technology to provide real-time verification of construction fieldwork. According to a press release from SiteAware, the construction industry represents a $1.3 trillion market share of the United States economy.

"SiteAware's DCV error prevention technology is disrupting the construction industry by dramatically accelerating schedules and streamlining work processes for all parties. In the next few years, everyone from contractors to developers will be using DCV to build without rework," says Zeev Braude, CEO of SiteAware, in a news release. "DCV gives the construction ecosystem access to data they've never had before, data that holds the key to the next jump in productivity for the industry." Click here to read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted